Lipid nanoparticles used to deliver RNA in vaccines
Researchers have developed a series of lipid nanoparticles, which encapsulate RNA, for effective and improved vaccine delivery.
List view / Grid view
Researchers have developed a series of lipid nanoparticles, which encapsulate RNA, for effective and improved vaccine delivery.
Increasing demand for convenient drug delivery, as well as an increase in diseases such as diabetes, has fuelled the global injectable drug delivery market.
With the approval of the treatment, Rybelsus, there is a new option for treating type 2 diabetes without injections.
A treatment for anaemia associated with chronic kidney disease in dialysis patients has been approved in Japan.
New vaccine patch has showed no negative side effects and could lead to a replacement of needle-based vaccination methods.
CPhI Worldwide will return for its 30th year on 5-7 November 2019 at Messe Frankfurt in Frankfurt, Germany.
GVOKE injection has received regulatory approval from the FDA for the treatment of severe hypoglycemia in patients with diabetes.
Bacteriostatic Water is being recalled because of a lack of sterilisation confirmation for some vials.
A team has developed a microrobot that is effective at targeting specific areas, so could be used in hyperthermia therapies when treating cancers.
New nanocapsules are a promising platform for many types of gene therapies due to their small size and superior stability.
A new study on DOX as a model drug has potential applications in the drug delivery field for better control drug release.
So-called 'nanodiamonds' could serve as a platform for diagnostic and therapeutic approaches for neurodegenerative diseases.
Dr Carsten Hopf and his team are using MALDI imaging in several applications, including drug metabolite and formulation distributions in tissues. This article investigates how this content-rich technique is enabling researchers to gain unique insights to facilitate faster and better drug discovery.
Mahfoozur Rahman and Sarwar Beg explain why we need to change tack from traditional formulation-driven development to a target-based approach in order to increase success with anticancer nanomedicine in the clinic.
New nano-immunotherapy has traversed the blood-brain barrier in mice, inducing an immune response in brain tissue surrounding tumours.